We offer both gel-based and gel-independent proteomic approaches in the discovery phase. Our services enable the rapid discovery, validation and identification of protein biomarkers. We also offer a number of fraction techniques that are used to explore low abundance proteins. OBS utilises the DECIDER database to integrate both genomic and proprietary derived proteomic data. DECIDER is an exceptionally powerful tool in the in silico validation and prioritization of biomarkers. The database is proprietary and is derived from the world's largest protein database on human body fluids and contains over 1,000,000 peptide sequences from 60 diseases along with information on 23,000 genes and 8 million SNPs. Using the DECIDER database in biomarker discovery programs greatly increases the ability to determine that candidate markers are robust and specific to a relevant condition.

Biomarkers can be further validated and quantified using MRM techniques. Synthetic analogues of the biomarker peptide are isotopically labeled and spiked into the sample and the intensity of these peptides is directly compared to the unlabelled marker for absolute quantitation.

Through a number of strategic alliances, we have demonstrated that our biomarkers can be successfully validated on a secondary platform (antibody based) in a very short period of time. The time taken from discovery to validation is typically less than 12 months.

We offer both fee-for-service models for protein biomarker discovery as well as strategic milestone-driven partnerships where we develop antibody or MRM assays. OBS can improve the time and cost-efficiency of drug development programs as well as facilitate early disease detection, prognosis and monitoring.